The company also launched animal health care, which is absolutely a new concept with outsourced marketing. In December 2007, they launched their new division 'Diagnozis' dealing in medical equipments & devices. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. The manufacturing unit at Baddi received WHO GMP certification for tablet/SVP/Liquid manufacturing. The company's Global Business unit at Derabassi got MHRA & TGA approval. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries.ĭuring the year 2007-08, the company's manufacturing unit at Parwanoo was upgraded as per WHO standards. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies.ĭuring the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They launched their product in Kenya and Senegal. They also launched the new marketing division namely Institutions & Hospitals division to look after the institutional sales.ĭuring the year, the company commissioned three new state of the art finished dosages facility at Samba in Jammu & Kashmir 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh.ĭuring the year 2006-07, the company developed and launched 65 new products and line extension. The new product launches included the launch of a unique combination of the Quinoline derivative, anti-diarrheal and anti-bacterial drug that was launched for the first time in India after completion of the successful clinical trials. They commenced commercial production in their new formulation facility at Jammu, J&K.ĭuring the year 2005-06, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The company opened first overseas office in New Jersey, USAĭuring the year 2004-05, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They entered into formulations export to six countries and filed patent in US for Clarithromycin. In the year 2003, the company launched another division by the name Ind-Swift Biosciences. In addition, they launched Institution/Hospital Division. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In addition, they launched a Marketing Division with the name Ind-Swift Health Care. In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. Ind-Swift Ltd was incorporated in the year 1986. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty. The company manufactures various dosage forms, including oral solutions and suspensions dry syrups and hard gelatin capsules tablets dermatologicals comprising creams, ointments, and gels eye and ear drops and injectables. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. Ind-Swift Ltd is an India-based pharmaceutical company. is NSE: ₹ 6.95, BSE: ₹ 7.00 with a current market capitalization of. Today's live share price for IND-SWIFT LTD.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |